Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have cancer that has spread to the brain (brain metastases), where the original cancer has been confirmed by laboratory testing of tumour tissue
- People who have received Gamma Knife (a type of targeted radiation treatment) within the last 4 months before joining the trial
- People who have a brain lesion that is suspected of either growing again or developing a complication called radionecrosis (tissue damage from radiation), meaning the lesion has grown by 25% or more in size
- People who have a lesion measuring at least 1 cm in the area that shows up when a contrast dye called gadolinium is used during a brain scan
Who may not be able to join:
- People who are pregnant
- People who have a history of a brain tumour that started in the brain (rather than spreading from elsewhere in the body)
- People who are unable to have an MRI scan, or who have a history of allergic reaction to contrast dye used in scans
- People who experience claustrophobia (fear of enclosed spaces, such as an MRI machine)
- People who are not able to give their own informed consent to participate
- People who have epilepsy or have recently had a stroke
- People who are currently participating in another clinical research study
- People who do not have health care insurance
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +330661884335
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Diagnostic performance of ASL quantitative analysis in brain metastasis following GK treatment : tumor perfusion with quantitative measurement (one value) of RCBF (relative cerebral blood flow) on the ASL sequence
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.